Financial budget plan for 2022
Jinhe Biotechnology Co.Ltd(002688)
Financial budget plan for 2022
According to the company’s medium and long-term strategic planning and the general requirements of the board of directors for the annual budget, the company’s 2022 financial budget plan is prepared as follows:
1、 Main financial budget indicators
1. The operating income was 25189004 million yuan
2. The total profit is 2202366 million yuan
Budget preparation scope:
Companies included in the budget preparation scope this year include Jinhe Biotechnology Co.Ltd(002688) (parent company), Inner Mongolia Jinhe Starch Co., Ltd., Inner Mongolia Jinhe Animal Pharmaceutical Co., Ltd., pharmgate Inc. and its subsidiaries, coldiagrosas, Inner Mongolia Jinhe Environmental Protection Technology Co., Ltd. and its subsidiaries, Jinhe Youben Biological Products Co., Ltd. and its subsidiaries Inner Mongolia Jinhe Animal Nutrition Technology Co., Ltd., Jinhe muxing (Chongqing) Biotechnology Co., Ltd. and Inner Mongolia Jinhe Pharmaceutical Technology Co., Ltd.
2、 Basic assumptions
1. There is no significant change in the current relevant national and local laws, regulations and systems followed by the company.
2. There is no significant change in the socio-economic environment of the company’s main business location and business areas.
3. There is no significant change in the industry situation and market situation of the company.
3、 Budget preparation Description:
1. Output: according to the market forecast in 2022, the specific varieties and specifications are determined by sales.
2. Sales volume and sales price: determined according to the existing customer orders for domestic and export sales and the analysis and judgment of the market. 3. Unit consumption of raw materials and energy: Based on the actual unit consumption of the previous year, fully consider process innovation
Financial budget plan for 2022
Energy saving transformation, management and consumption reduction shall be determined.
4. Purchase price of raw materials and energy: forecast according to market trend.
5. Implement the current tax policy.
6. The exchange rate is estimated based on the judgment of the economic situation and monetary policy of China and the United States.
In 2022, the company will rely on the strategic adjustment of industrial structure and layout, regional advantages and scale advantages to reduce production costs. Coordinate the layout of markets outside China, strengthen marketing, further consolidate its leading position in the industry and dominate the market pricing discourse. Actively promote the research and development of new products, make use of the existing marketing network, carry out e-commerce platform sales, and vigorously develop end customers.
4、 Comparison between the company’s financial budget in 2022 and its operating results in 2021
Unit: 10000 yuan
Increase / decrease rate of planned amount in 2022 and actual amount in 2021 (%)
1、 Operating income 2518900420779887 21.22%
Less: operating cost 1765752314269218 23.75%
Sales expense 13967161225052 14.01%
Administrative expenses 21957192291773 – 4.19%
R & D expenses 1078703722505 49.30%
Financial expenses 585742648895 – 9.73%
2、 Total profit 22023661429108 54.11%
3、 1221358% net profit
4、 Net profit attributable to shareholders of the parent company 1579115939924 68.00%
The above financial budget is the internal management control assessment index of the company’s business plan for 2022 and does not represent the company’s profit forecast for 2022. Whether it can be realized depends on many factors such as changes in market conditions and the efforts of the management team. There is great uncertainty. Investors should pay special attention to it.
Jinhe Biotechnology Co.Ltd(002688)
Board of directors
April 20, 2022
